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PAO and whether perfusion contributes to new bone formation in the
acetabular fragment. The purpose of this study was to quantify blood
perfusion and bone formation before and after PAO analysed by Positron
Emission Tomography (PET) combined with Computed Tomography
(CT).
Methods: Twelve dysplastic patients (nine women) were included
consecutively in the study all operated by the senior author. Median
age was 33 (23–55) years. Initially, two patients were PET scanned in
a pilot study to test our models for calculation of the physiological
parameters. The following ten patients had their hip joints PET/CT
scanned immediately before PAO and 3–4 weeks after. Due to patients
moving on the scanner bed while scanning, data of sufﬁciently high
quality was only available for six out of ten. [O-15]-water was used
to quantify blood perfusion and [F-18]-ﬂuoride was used to produce
quantitative images interpreted as new bone formation in/around
the acetabular fragment. The perfusion [ml blood/min/ml bone] was
determined from a one-compartment model, with the parameters:
K1, k2 and the delay. The ﬂuoride-clearance per volume bone (Ki)
[ml blood/min/ml bone] was determined by applying Patlak graphical
analysis to the ﬂuoride scan, ﬁtting the data from 45 to 90 min.
Results: The blood perfusion on the operated acetabulum before surgery
was 0.07±0.02ml/min/ml, and after surgery 0.19±0.03ml/min/ml
(p < 0.00). Blood perfusion on the non-operated acetabulum was
0.07±0.02ml/min/ml before PAO and 0.07±0.02ml/min/ml after surgery
(p = 0.47).
The ﬂuoride-clearance per volume bone on the operated acetabulum was
0.02±0.01ml/min/ml preoperatively, and 0.06±0.01ml/min/ml postop-
eratively (p < 0.00). Fluoride-clearance on the non-operated acetabulum
was 0.01±0.01ml/min/ml before PAO and 0.02±0.01ml/min/ml after PAO
(p =0.49).
Conclusions: Blood perfusion and new bone formation increased
signiﬁcantly in the acetabular fragment demonstrating that blood
perfusion to the acetabular fragment is not critically compromised after
minimally invasive PAO a.m. Soballe. Three to four weeks after PAO, bone
formation in the acetabular fragment on the operated side had increased
signiﬁcantly. This is the ﬁrst paper applying PET/CT to quantify blood
perfusion and bone formation before and after PAO.
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SMOOTHENING OF PERIARTICULAR BONE: BLOCKADE OF THE
HEDGEHOG PATHWAY INHIBITS OSTEOPHYTE FORMATION IN
ARTHRITIS
G. Ruiz-Heiland1, A. Horn1, P. Zerr1, W. Hofstetter2, W. Baum1, M. Stock1,
J. Distler1, F. Nimmerjahn1, G. Schett1, J. Zwerina3. 1Univ. of Erlangen,
Erlangen, Germany; 2Univ. of Bern, Bern, Switzerland; 3Hanusch Hosp.,
Vienna, Austria
Purpose: Osteophyte formation is a common phenomenon in arthritis.
Bone formation by endochondral ossiﬁcation is considered a key
pathophysiologic process to form osteophytes. We hypothesized that
inhibition of Smoothened (Smo), a key component of the hedgehog
pathway inhibits osteophyte formation as the hedgehog pathway
mediates endochondral ossiﬁcation.
Methods: We induced arthritis in 8 weeks old C57/BL6 mice by serum
transfer (KxBN model). Mice were then treated by daily administration
of either vehicle or LDE 223, a speciﬁc small molecule inhibitor for Smo,
over 2 weeks starting at the onset of disease. Clinical course of arthritis,
histological and molecular changes of bone in the affected joints as well
as systemic bone changes were assessed.
Results: Serum transfer induced arthritis led to severe osteophyte
formation within 2 weeks of onset. Blockade of Smo inhibited hedgehog
signaling in vivo and also signiﬁcantly inhibited osteophyte formation,
whereas the clinical and histopathologic signs of arthritis were not
affected. Also, systemic bone mass did not change. Smo inhibitor
particularly blocked the formation of hypertrophic chondrocytes and
collagen type X expression.
Conclusions: Our data indicate that blockade of hedgehog signaling
by targeting Smo speciﬁcally inhibits osteophyte formation in arthritis
without affecting inﬂammation and without eliciting bone destruction
at the local and systemic level. Blockade of SMO may thus be considered
as a strategy to speciﬁcally inﬂuence the periosteal bone response in
arthritis associated with bone apposition.
Cartilage Biology & Biochemistry
198
TNFa INDUCES SIRT1 CLEAVAGE IN HUMAN OSTEOARTHRITIC
CHONDROCYTES
M. Dvir-Ginzberg1, O. Gabay2, H. Oppenhiemer1, H. Meir1, V. Gagarina2,
E. Lee2, A. Haze1, L. Kandel3, M. Liebergall3. 1Hebrew Univ. of Jerusalem,
Jerusalem, Israel; 2NIAMS, Bethesda, MD, USA; 3Hadassah Mount Scopus
Hosp., Jerusalem, Israel
Purpose: Osteoarthritis (OA) is a common degenerative joint disease
of articular cartilage (AC) characterized by a disrupted homeostasis of
extracellular matrix (ECM) synthesis and breakdown. It is often thought
that mechanical wear and tear of AC elicits OA pathology. However,
increasing reports indicate that synovial inﬂammation occurs in OA,
resulting in augmented levels of proinﬂammatory cytokines (mainly
TNFa and IL-1b) within synovial ﬂuid. Given that the NAD-dependent
protein deacetylase SirT1 promotes cartilage-type ECM expression and
chondrocyte survival, we postulate its function is altered in chondrocytes
exposed to proinﬂammatory cytokines, as TNFa.
Methods: TNFa-treated and untreated human osteoarthritic chondro-
cytes were analyzed for cartilage-speciﬁc gene expression, SirT1 activity
and ChIP analyses at the collagen 2a1 enhancer site. Human chondrocytes
transfected with an N-terminal Flag-tag SirT1 expression vector, were
treated with or without TNFa and analyzed by immunoblot for the
presence of SirT1. Protein extracts were immunoprecipitated for SirT1
following TNFa-treatment and analyzed via mass-spectroscopy and
Edman sequencing. In-vitro analysis of SirT1 activity and cleavage
was assayed in the presence of active Cathepsin B.Confocal images of
SirT1 monitored its subcellular trafﬁcking following TNFa stimulation.
Co-immunoﬂuorescent staining and confocal visualization was carried
out for Cathepsin B, mitochondrial Cox IV and Lysosome-associated
membrane protein I (LAMP-I) together with SirT1. Human chondrocyte
were tested for apoptosis via FACS analysis for Annexin V and
immunoblotting for active caspase 3 and 8. TNFa treated mitochondrial
extracts were obtained and immunopreciptated to detect the presence
of cleaved-SirT1. Finally human osteoarthritic and normal samples were
analyzed for the presence of active Cathepsin B, MMP13 and cleaved-
SirT1.
Results: TNFa-treated chondrocytes had impaired SirT1 enzymatic
activity and displayed full-length SirT1 protein (110kDa, FL-SirT1)
and a smaller 75kDa SirT1 fragment (i.e 75kDa SirT1). 75kDa SirT1
was generated via Cathepsin B-mediated cleavage at residue 533,
following TNFa stimulation. Confocal images revealed that 75kDa SirT1
was exported to the cytoplasm and colocalized with mitochondrial
membrane protein Cox IV, following TNFa stimulation. Prohibiting
nuclear export of 75kDa SirT1 via Leptomycine B or reducing its
protein levels in the presence of TNFa, led to a 10-fold increase in
apoptotic chondrocytes. Finally, Cathepsin B, responsible for 75kDa
SirT1 generation, was found elevated in TNFa-treated and OA-derived
chondrocytes vs. untreated and normal chondrocytes, respectively. As an
additional proof of principle, we show that normal human chondrocytes
exposed to synovial ﬂuid derived from OA patients generate 75kDa SirT1
fragment.
Conclusion: These data indicate that TNFa, a cytokine that mediates
joint inﬂammation in OA, induces Cathepsin B-mediated cleavage of
SirT1, resulting in a cytoplasmic 75kDa SirT1 fragment with impaired
enzymatic activity. The impaired enzymatic activity of 75kDa SirT1
correlates with reduced cartilage-ECM gene expression evident in TNFa
treated chondrocytes. In parallel, our data show that the stable 75kDa
SirT1 fragment promotes chondrocyte survival when exposed to TNFa.
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THE ROLE OF THE PROGRESSIVE ANKYLOSIS PROTEIN (ANK) IN
OSTEOARTHRITIS
K. Campbell, S. Hadley, T. Minashima, T. Kirsch. NYU Sch. of Med., New
York, NY, USA
Purpose: Currently there are no treatments available for osteoarthritis
(OA). In order to establish new therapeutic strategies for the treatment of
OA, a better understanding of the cellular and molecular changes during
OA progression is required. The progressive ankylosis protein (ANK) is a
